Literature DB >> 22851661

Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.

Fadhil G Al-Amran1, Najah R Hadi, Ali M Hashim.   

Abstract

OBJECTIVES: The aim of this study was to assess the possible protective effect of montelukast against haemorrhagic shock-induced acute lung injury by interfering with inflammatory and oxidative pathways. Acute lung injury following haemorrhagic shock/resuscitation is an important contributor to late morbidity and mortality in trauma patients. Haemorrhagic shock (HS), followed by resuscitation, is considered to be an insult that frequently induces systemic inflammatory response syndrome and oxidative stress, resulting in multiple-organ dysfunction syndrome, including microvascular changes and microscopic damage termed acute lung paraynchymal injury. Montelukast is a cysteinyl leukotriene receptor antagonist that exerts an anti-inflammatory and antioxidant influence.
METHODS: Eighteen adult albino rats were assigned to three groups of six. In Group I, the 'sham' group, rats underwent all the surgical procedures but neither haemorrhagic shock nor resuscitation was carried out. Group II--the 'HS' induced, untreated group--was the control and underwent HS for one hour before being resuscitated with Ringer's lactate for one hour. Group III--the 'montelukast' group--underwent HS and treatment with montelukast (7 mg/kg i.p. injection) 30 min before the induction of HS, with the same dose repeated just before the reperfusion period. At the end of the experiment, two hours after completion of resuscitation, blood samples were collected for measurement of serum tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The trachea was then isolated and bronchoalveolar lavage was carried out for measurement of leukotriene B(4) (LTB(4)), leukotriene C(4) (LTC(4)) and total protein. The lungs were harvested and the left lung was homogenized for measurement of malondialdehyde (MDA) and reduced glutathione (GSH) and the right lung was fixed in 10% formalin for histological examination.
RESULTS: Montelukast treatment (Group III) significantly reduced the total lung injury score, compared with the HS group (Group II) (P < 0.05). Montelukast also significantly decreased serum TNF-α and IL-6; lung MDA; bronchoalveolar lavage fluid (BALF) LTB(4), LTC(4) &amp; total protein compared with the HS group (P < 0.05). Montelukast treatment significantly inhibited decrease in the lung GSH levels, compared with the HS group (P < 0.05).
CONCLUSIONS: The results of the present study reveal that montelukast may ameliorate lung injury in shocked rats by interfering with inflammatory and oxidative pathways, implicating the role of leukotrienes in the pathogenesis of haemorrhagic shock-induced lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851661     DOI: 10.1093/ejcts/ezs312

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

1.  Montelukast reduces inhaled chlorine triggered airway hyperresponsiveness and airway inflammation in the mouse.

Authors:  Yoichiro Hamamoto; Satoshi Ano; Benoit Allard; Michael O'Sullivan; Toby K McGovern; James G Martin
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

2.  Role of cysteinyl leukotriene signaling in a mouse model of noise-induced cochlear injury.

Authors:  Jung-Sub Park; Seo-Jun Kang; Mi-Kyoung Seo; Ilo Jou; Hyun Goo Woo; Sang Myun Park
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

3.  Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.

Authors:  M A Saad; R M Abdelsalam; S A Kenawy; A S Attia
Journal:  Neurochem Res       Date:  2014-11-18       Impact factor: 3.996

4.  Pro-inflammatory interleukins in middle ear effusions from atopic and non-atopic children with chronic otitis media with effusion.

Authors:  Beata Zielnik-Jurkiewicz; Wanda Stankiewicz-Szymczak
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-16       Impact factor: 2.503

5.  Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway.

Authors:  Yanbo Wang; Hongwei Liang; Fangfang Jin; Xin Yan; Guifang Xu; Huanhuan Hu; Gaoli Liang; Shoubin Zhan; Xiuting Hu; Quan Zhao; Yuan Liu; Zhen-You Jiang; Chen-Yu Zhang; Xi Chen; Ke Zen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

6.  The anti-inflammatory and antioxidant effects of Montelukast on lung sepsis in adult mice.

Authors:  Zainab Ali Alnfakh; Dhefaf Hameed Al-Mudhafar; Rana Talib Al-Nafakh; Abdullah Elttayef Jasim; Najah Raiesh Hadi
Journal:  J Med Life       Date:  2022-06

7.  Zafirlukast in combination with pseudohypericin attenuates spinal cord injury and motor function in experimental mice.

Authors:  Xiao-Gang Chen; Fu Hua; Shou-Guo Wang; Yong-Yi Xu; Hai-Tao Yue; Jin Sun
Journal:  Drug Des Devel Ther       Date:  2018-08-01       Impact factor: 4.162

Review 8.  Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.

Authors:  Rakesh K Singh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 9.  Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.

Authors:  A J Theron; H C Steel; G R Tintinger; C M Gravett; R Anderson; C Feldman
Journal:  J Immunol Res       Date:  2014-05-25       Impact factor: 4.818

10.  The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.

Authors:  Julia Marschallinger; Barbara Altendorfer; Edward Rockenstein; Miriam Holztrattner; Julia Garnweidner-Raith; Nadine Pillichshammer; Iris Leister; Birgit Hutter-Paier; Katharina Strempfl; Michael S Unger; Mansoor Chishty; Thomas Felder; Mary Johnson; Johannes Attems; Eliezer Masliah; Ludwig Aigner
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.